Schering Corporation

Merck Sharp + Dohme Corp.

Intervet Inc.

Mochida Pharmaceutical Co., Ltd.

Intervet International B.v.

Merck Canada Inc.

Mariappan Chelliah

Samuel Chackalamannil

Yan Xia

Martin C Clasby

William J Greenlee

Tin-Yau Chan

Yuguang Wang

Keith A Eagen

Michael P Dwyer

Unmesh G Shah

Srikanth Venkatraman

Zhuyan Guo

Santhosh Francis Neelamkavil

Fumihiko Saitoh

Henry M Vaccaro

Tomokazu Hirabayashi

Hidemitsu Nishida

Enrico P Veltri

Charles Jayne

Brian Alexander McKittrick

Yongxin Han

Duane A Burnett

Hubert B Josien

Jack D Scott

Jason M Cox

Wenxue Wu

Patrick A Pinto

John S Debenham

Kartik M Keertikar

Clare London

Shouwu Miao

Linda Brockunier

Francisco Velazquez

Christopher Joseph Sinz

Thomas A Bara

Ping Lan

Sathesh P Bhat

Austin Chen

Michael P Graziano

Hong Dong Chu

Zhongxiang Sun

Dipshikha Biswas

Murali Rajagopalan

Haiyan Pu

Karen M Marcantonio

Li Wang

Xiaobang Gao

Teddy Kosoglou

Michael A Plotkin

Vince J Colandrea

Madhu Chintala

Liyuan Wang

Keith Eagan

Keith Eagen

Unmesh Shah

Skikanth Venkatraman

The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included. 

Substituted spiropiperidinyl compounds useful as GPR120 agonists

The present invention relates to hepatitis C virus (HCV) NS3 protease inhibitors containing a spirocyclic moeity, uses of such compounds, and synthesis of such compounds.

HCV NS3 protease inhibitors

The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt or a solvate thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.

Morpholinone compounds as factor IXA inhibitors

Morpholinone compounds as factor IXa inhibitors

The present invention relates to novel heterocyclic compounds of Formulae (I): (Chemical formula should be inserted here as it appears on abstract in paper form) Formula (I) as disclosed herein, or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are pharmaceutical compositions comprising said compounds, and methods for using said compounds for treating or preventing a thromboembolic disorder. 

4, 5, 6-trisubstituted pyrimidine derivatives as factor IXa inhibitors

Fused-ring, heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein

Fused ring thrombin receptor antagonists

Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein

Bicyclic and tricyclic derivatives as thrombin receptor antagonists

The present invention relates to novel heterocyclic compounds of Formulae I-III; as disclosed herein or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are pharmaceutical compositions comprising said compounds, and methods for using said compounds for treating or preventing a thromboembolic disorder. 

Heterocyclic compounds as factor IXA inhibitors

Substituted bicyclic and tricyclic modified himbacine derivative of the formula: or a pharmaceutically acceptable salt or solvate of said compound whereinrepresents an optional double bond and wherein E, F, G, Z, J, X, R, R, R, R, R, R, B and Het are herein defined are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other agents is also claimed.

Substituted bicyclic and tricyclic thrombin receptor antagonists

A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, is useful in treating diseases, disorders, or conditions such as obesity, metabolic disorders, addiction, diseases of the central nervous system, cardiovascular disorders, respiratory disorders, and gastrointestinal disorders.

Cannabinoid receptor modulators

Monocyclic and bicyclic himbacine derivatives of the formula or a pharmaceutically acceptable salt or solvate of said compound wherein

Monocyclic and bicyclic himbacine derivatives useful as thrombin receptor antagonists

Spirocyclic thrombin receptor antagonists

Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt thereof, wherein:

Thrombin receptor antagonists

A series of compounds represented by the structural formulas and pharmaceutically acceptable isomers, salts, solvates and polymorphs thereof are disclosed. Also disclosed are pharmaceutical compositions containing said compounds and their use as thrombin receptor antagonists and binders to cannabinoid receptors.

Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein z,1 represents an optional double bond, the dotted line is optionally a bond or no bond, resulting in a double bond or a single bond, as permitted by the valency requirement and wherein A, B, G, M, X, J, n, Het, R, R, R, Rand Rare herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.

Growing community of inventors

Edison, NJ, United States of America

Mariappan Chelliah